ライフサイエンスコーパス: bilirubin

1 trition requirements, cause of GF, and serum bilirubin.

2 a yellowing of the skin due to a buildup of bilirubin.

3 with liver disease, AKI, and highly elevated bilirubin.

4 imated glomerular filtration rate, and serum bilirubin.

5 es while being substantially less toxic than bilirubin.

6 1A1 (UGT1A1) and the inability to metabolize bilirubin.

7 ost portal veins, with no elevation of serum bilirubin.

8 r characterized by an inability to conjugate bilirubin.

9 sponsible for the reduction of biliverdin to bilirubin.

10 isomerization, similar to that observed for bilirubin.

11 r, PFOA was associated with decreased direct bilirubin.

12 (P < 0.05) decrease was only noted for total bilirubin.

13 transferase, gamma-glutamyl transferase, and bilirubin.

14 th circulating levels of CA19-9, albumin and bilirubin.

15 15); PVT patients displayed higher levels of bilirubin 0.53 mg/dl p < 0.001 (95% CI 0.23 to 0.78), IN

16 861.8 +/- 813.7 U/L; p </= 0.01), and total bilirubin (0.13 +/- 0.05 vs 0.30 +/- 0.14 mg/dL; p </= 0

17 ferase (AST; 26 versus 21, P = 0.01), direct bilirubin (0.13 versus 0.1, P = 0.01), prothrombin time

18 death included higher than 115 mumol/L serum bilirubin 2-5 days after biliary stenting (HR 3.274, P=0

19 o [1.2, P < 0.001; 1.1, P = 0.001] and total bilirubin (2.7, P = 0.001; 2.1, P = 0.05)).

20 I biliary atresia with jaundice (total serum bilirubin, 22.2 mg/dL), hypoalbuminemia (serum albumin l

21 mes the upper limit of normal) with a normal bilirubin 28 days after starting MLE4901, which normalis

22 expression signature, combined with level of bilirubin 3 months after hepatoportoenterostomy, identif

23 ratio (1.5 and 1.2, respectively) and total bilirubin (4.6 and 2.7) were significantly greater compa

24 Bilirubin, a key biomarker for the jaundice and its clin

25 isk of jaundice, a condition in which excess bilirubin accumulates in blood.

26 parameters like total leucocyte count, urea, bilirubin, alanine transaminase, aspartate transaminase,

27 ose To construct a nomogram with the albumin-bilirubin (ALBI) grade to assess the long-term outcomes

28 te tool (PREsTo) consists of nine variables: bilirubin, albumin, serum alkaline phosphatase (SAP) tim

29 rcentage of B(T) correlated inversely to the bilirubin-albumin equilibrium association binding consta

30 risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, pre

31 Univariate analysis identified serum bilirubin, alkaline phosphatase, and urinary bilirubin a

32 atic parameters ALP, GGT, ALT, AST and total bilirubin, also considering the adverse events.

33 count, raised serum ALT, raised serum total bilirubin and a lack of endoscopy were independent predi

34 a pleotropic enzyme converting biliverdin to bilirubin and a signaling molecule that has cytoprotecti

35 POD3 of 7 total bilirubin and alanine aminotransferase; POD3 aspartate a

36 liver triglyceride content and elevated ALT, bilirubin and alkaline phosphatase due to three hepatic

37 e times the upper limit of normal with total bilirubin and alkaline phosphatase two or more times the

38 serum markers of liver injury, particularly bilirubin and ALP, are used to stratify risk and assess

39 Unconjugated bilirubin and ammonia were or tended to be elevated in F

40 ive bile production and biliary secretion of bilirubin and bicarbonate were significantly higher afte

41 o determine the relationship between center, bilirubin and calculated MELD-Na.

42 Loss of AQP2 in AKI patients with elevated bilirubin and CN might be the result of toxic effects of

43 n collecting ducts in patients with elevated bilirubin and CN.

44 ditionally to improved laboratory variables (bilirubin and creatinine), the short-term mortality (up

45 ansferase, aspartate aminotransferase, total bilirubin and direct bilirubin levels as well as signifi

46 y composition, biochemical assays to measure bilirubin and fatty acids, MitoTracker-based mitochondri

47 lower percentage haemocrit and higher total bilirubin and free haemoglobin concentration (P < 0.05 f

48 correlated with unconjugated and conjugated bilirubin and INR (p < 0.05), except HAZ or LAZ.

49 ients, PCLD patients had significantly lower bilirubin and international normalized ratio at waitlist

50 or linear trend in the AUC of serum indirect bilirubin and iron levels).

51 CN II exhibit residual capacity to conjugate bilirubin and may present a normal life expectancy.

52 centrations and an average increase of total bilirubin and phosphate concentration towards the end of

53 important biomarkers for liver function are bilirubin and prothrombin time expressed as Internationa

54 Postoperative serum bilirubin and prothrombin time-international normalized

55 length of hospital stay, postoperative serum bilirubin and PT-INR, as well as infectious and overall

56 ssion post-CPB was associated with low serum bilirubin and reduced preoperative expression of biliver

57 ositive association was found between direct bilirubin and T2D risk comparing extreme quartiles, simi

58 bilirubin, alkaline phosphatase, and urinary bilirubin and urobilinogen as predictive factors for the

59 with hemolysis (lactate dehydrogenase, total bilirubin) and inflammation (tumor necrosis factor-alpha

60 New albumin, bilirubin, and alkaline phosphatase grade 3/4 toxicities

61 ary function (total bile production, biliary bilirubin, and bicarbonate), and significantly lowered l

62 latelet counts, C-reactive protein, albumin, bilirubin, and CA19-9 levels, and also follow-up informa

63 o determine the relationship between center, bilirubin, and calculated MELD-sodium (MELD-Na) score.

64 Elevations of serum transaminases, bilirubin, and creatine kinase were infrequent and simil

65 port of many compounds, such as fatty acids, bilirubin, and heme.

66 for degradation of heme to carbon monoxide, bilirubin, and iron, is an important regulator of inflam

67 as HDL cholesterol, free fatty acids, FGF21, bilirubin, and lactate depend on the microbiome.

68 ology Score 2, plasma lactate deshydrogenase bilirubin, and serum ferritin.

69 serum samples were analyzed for creatinine, bilirubin, and sodium in all transplant centers within U

70 for measurement of the concentration of free bilirubin, and the analysis can be performed in less tha

71 AKI patients with normal bilirubin, elevated bilirubin, and the diagnosis of CN revealed loss of aqua

72 acteristic curve, 0.63) followed by albumin, bilirubin, and WBC count (area under the receiver operat

73 (GGT), alkaline phosphatase (ALP) and total bilirubin are also reported, although less frequently.

74 Bilin chromophores and bilirubin are involved in relevant biological functions

75 lysis identified baseline cholinesterase and bilirubin as the most important variables (forest-averag

76 yed increased plasma levels of ALT, ALP, and bilirubin as well as a significantly higher collagen con

77 icators on univariate analysis were albumin, bilirubin, ascites, tumor size 5 cm or smaller, focality

78 parameters (international normalized ratio, bilirubin, aspartate aminotransferase, alanine aminotran

79 amino acids, cell-free DNA, creatinine, and bilirubin, assigned for the predominant RS-bands were al

80 Median serum ALT and total bilirubin at presentation were 462 U/L (IQR 266-790) and

81 Unbound ("free") bilirubin (B(f) ) was measured in patient sera to charac

82 to characterize the binding of unconjugated bilirubin (B(T) ) to albumin (A) and validate their mola

83 0.03; P = .01), lower blood concentration of bilirubin (B: -0.01; 95% CI: -0.02, -0.003; beta: -0.04;

84 an increase in alanine transaminase or total bilirubin between both CSL112 arms and placebo was withi

85 In addition to the toxic effect of Bilirubin (BIL), it has antioxidant properties that were

86 Alterations in the bilirubin/biliverdin ratio and ergothioneine can indicat

87 Bilirubin binds and activates two MRGPRs, mouse MRGPRA1

88 ntification of penicillin anaphylaxis, urea, bilirubin, biomarkers related to human intoxication, tum

89 1 month included operation type, NAS >/= 5, bilirubin, body mass index, hemoglobin A1C, and dyslipid

90 we developed a sensitive genetically encoded bilirubin (BR)-inducible fluorescence sensor (eUnaG) to

91 and heme degradation products, particularly bilirubin by using our recently created mouse model, whi

92 ole enzyme responsible for the metabolism of bilirubin, can be induced following activation of Nrf2.

93 reased platelet count), hepatic injury (high bilirubin), circulatory shock (low mean blood pressure a

94 Higher bilirubin, coagulopathy, leukocytosis, and thrombocytope

95 ue (including grade 3 in three patients) and bilirubin concentration increases (including grade 3-4 i

96 lkylating agent) and last available pre-HSCT bilirubin concentration of greater than or equal to the

97 r) were then utilized to calculate the total bilirubin concentration.

98 ic acid can improve alkaline phosphatase and bilirubin concentrations but does not alter the disease

99 Total bilirubin concentrations were stabilised, with significa

100 nsferase levels, and two (17%) had increased bilirubin concentrations.

101 iterature on the theranostic applications of bilirubin-conjugated nanoparticles and the basis and mec

102 ays out the possible translational future of bilirubin-conjugated nanoparticles in therapy and diagno

103 We also show that bilirubin conjugates activate ENaC.

104 Free bilirubin could be detected in human blood serum with th

105 The primary endpoint was the change of serum bilirubin, creatinine and serum BUN levels before and af

106 lysis, thrombophilia, and inflammation (LDH, bilirubin, D-dimer, C-reactive protein [CRP]) improved.

107 aminotransferase (AST), day-1 lactate, day-3 bilirubin, day-3 international normalized ratio (INR), a

108 cholestasis was defined as sustained direct bilirubin (DB) <2 mg/dL, and treatment failure as liver

109 ase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL) with minimal bile duct damage in the AN

110 Serum total bilirubin decreased after PEBD in FIC1 (8.1 +/- 4.0 vs.

111 Removing bilirubin decreased the pruritogenic capacity of patient

112 ecently, isolated intermediates of oxidative bilirubin degradation, known as PDPs (propentdyopents),

113 he capabilities to not only quantitate total bilirubin (Deming-regression slope of 0.95, R(2) = 0.990

114 genes involved in intestinal maturation and bilirubin detoxification.

115 c acid methyl ester, a simplified model of a bilirubin dipyrrinone subunit responsible for a lumirubi

116 In addition, the isomeric bilirubin dipyrrinone subunits were found to possess imp

117 1, in combination with the overproduction of bilirubin during the developmental stage, acts as a bott

118 logical analysis of AKI patients with normal bilirubin, elevated bilirubin, and the diagnosis of CN r

119 ents, whereas alkaline phosphatase and total bilirubin elevations were rare.

120 ts in the deferred treatment group had total bilirubin elevations.

121 developmental stage, acts as a bottleneck to bilirubin elimination and predisposes the infant to high

122 Acute bilirubin encephalopathy (ABE) and kernicterus spectrum

123 al hyperbilirubinemia (SNH) and the onset of bilirubin encephalopathy and kernicterus result in part

124 demonstrate that pathophysiologic levels of bilirubin excite peripheral itch sensory neurons and eli

125 Bilirubin exerted its effects by recruiting and dissocia

126 signed to measure the concentration of total bilirubin from several drops of blood at the point of ca

127 for severe neonatal jaundice to remove toxic bilirubin from the blood.

128 responsible for elimination of unconjugated bilirubin from the body by glucuronidation.

129 ggshell pigments: yellow-brown tetrapyrrolic bilirubin from the guacamole-green eggshells of Eudromia

130 hroughput coregulator analysis, we show that bilirubin functions as a molecular switch for the nuclea

131 Complications, including iron overload, bilirubin gallstones, extramedullary hematopoiesis, pulm

132 an autosomal recessive inherited disorder of bilirubin glucuronidation which has not been investigate

133 ed to study medication, and no elevations in bilirubin greater than 2 x the upper limit of normal wer

134 DILI were defined as serum ALT > 5x or serum bilirubin > 1.5x upper limit of normal in the setting of

135 ement therapy, and 28% had liver impairment (bilirubin >34 mumol/L), each of these parameters definin

136 Patients with severe AFOCHB with bilirubin >50 umol/l, ALT >10x upper limit of normal, an

137 d biochemical markers of severe cholestasis (bilirubin >=100 mumol or alkaline phosphatase >3-fold th

138 Unbound bilirubin had a nonlinear relationship to B(T) (R(2) = 0

139 Increased serum bilirubin has been shown to be a negative predictive fac

140 Serum bilirubin higher than 115 mumol/L 2-5 days after the pro

141 weight among left lobes, higher preoperative bilirubin, higher portal reperfusion pressure, higher do

142 Unlike bilirubin, however, the phylloxanthobilin Z isomers phot

143 erase (HR 4.22, p 0.016), raised serum total bilirubin (HR 5.79, p 0.008) and lack of an endoscopic p

144 ely measures free ionic bilirubin ("unbound" bilirubin - i.e., bilirubin not complexed to albumin or

145 tly benign, excessively high levels of serum bilirubin in a small percentage of newborns can cause bi

146 inical study using BiliSpec to measure total bilirubin in neonates at risk for jaundice at Queen Eliz

147 was a moderate transient elevation in serum bilirubin in one participant.

148 ers the clinically-relevant concentration of bilirubin in serum (5-500 muM).

149 Knowing the concentration of bilirubin in serum is important in evaluating the health

150 ver the clinically-relevant concentration of bilirubin in serum).

151 ometric sensor for the determination of free bilirubin in serum.

152 l studies have demonstrated the potential of bilirubin in theranostic applications.

153 VRA), the enzyme that converts biliverdin to bilirubin, in patient's leukocytes.

154 In newborns with CN1, unconjugated bilirubin increased 4.3 +/- 1.1 mg/dL per day.

155 nvestigating molecular mechanisms underlying bilirubin-induced encephalopathy, and searching for pote

156 Bilirubin-induced neurologic dysfunction (BIND) and kern

157 in a small percentage of newborns can cause bilirubin-induced neurologic dysfunction, potentially le

158 een developed to make it possible to examine bilirubin-induced neurotoxicity from multiple directions

159 Age, bilirubin, INR, and creatinine (ABIC) score was B or C i

160 s correlation coefficient analysis confirmed bilirubin interfered with creatinine, with worsening agr

161 ortality between MELD-GRAIL-Na (re-estimated bilirubin, international normalized ratio [INR], sodium,

162 cation, MEAF is a continuous score, based on bilirubin, international normalized ratio, and alanine a

163 livers functioned, and serum transaminases, bilirubin, international normalized ratio, and lactate l

164 (Model for End-Stage Liver Disease and age, bilirubin, international normalized ratio, creatinine sc

165 Serum bilirubin is a potent endogenous antioxidant and has bee

166 We also found that bilirubin is a selective ligand for PPARalpha and does n

167 Bilirubin is a yellow-colored metabolite of heme degrada

168 Owing to the fact that bilirubin is metabolized solely through glucuronidation

169 Bilirubin is predominantly formed in the liver as a resu

170 , caused by the accumulation of unconjugated bilirubin, is one of the most common clinical diagnoses

171 is association, the pruritogenic capacity of bilirubin itself has not been described, and no bilirubi

172 f predicted risk on the continuous variables bilirubin level and cholinesterase level was determined.

173 ter reductions from baseline in the indirect bilirubin level and percentage of reticulocytes than the

174 The median bilirubin level at diagnosis of EASL-alone ACLF was 2.0

175 sk factors for adverse outcomes in AC: total bilirubin level greater than 10 mg/dL and white blood ce

176 nt greater than 20000 cells/microL and total bilirubin level greater than 10 mg/dL are independent pr

177 onship between maternal exposure and newborn bilirubin level is also quantitated.

178 , 65-195 U/L [1.1-3.3 mukat/L]), and a total bilirubin level of 1.5 mg/dL (25.7 umol/L) (normal range

179 e, 65-195 U/L [1.1-3.3 ukat/L]), and a total bilirubin level of 1.5 mg/dL (25.7 umol/L) (normal range

180 attern on liver function tests, with a total bilirubin level of 3.5 mg/dL (59.9 umol/L) (normal range

181 e, 13.5-18.0 g/dL [8.38-11.17 mmol/L]) and a bilirubin level of 62 micromol/L (normal range, 3-17 mic

182 io, 3.4; 95% CI, 1.2-9.5; P = .02) and total bilirubin level of more than 10 mg/dL (odds ratio, 5.4;

183 No elevations in the bilirubin level of more than twice the upper limit of th

184 on ventilator and dialysis and had a higher bilirubin level than other candidates.

185 ecile, glomerular filtration rate, and total bilirubin level were included in a simplified model and

186 lasma PfHRP2 level, parasitemia level, total bilirubin level, and RCD at a shear stress of 1.7 Pa wer

187 least 15% from baseline, and a normal total bilirubin level.

188 ferent with respect to overall survival were bilirubin levels (p<0.001), pretreatment transaminase le

189 rticipants with 2,532 diabetes cases), serum bilirubin levels (total, direct and indirect) increased

190 Baseline bilirubin levels above 1.5 mg/dL were associated with a

191 its prognostic significance in patients with bilirubin levels above 200 mumol/L.

192 serum showed a hepatic effect; e.g. reduced bilirubin levels and albumin/globulin ratio.

193 ort the protective association between serum bilirubin levels and incident T2D in the middle-aged and

194 l and prospective associations between serum bilirubin levels and T2D risk in the Dongfeng-Tongji (DF

195 For unknown reasons, bilirubin levels are negatively associated with obesity

196 aminotransferase, total bilirubin and direct bilirubin levels as well as significant reduction of ser

197 Alkaline phosphatase and bilirubin levels correlate with the risk of liver transp

198 with a positive screening result defined as bilirubin levels exceeding derived 95th percentile refer

199 with a positive screening result defined as bilirubin levels greater than the stage 1 result or grea

200 Bilirubin levels increase linearly with exposure time be

201 The mean difference between bilirubin levels measured with BiliSpec and the referenc

202 principal component analysis, which included bilirubin levels or clinical icterus, and lactate dehydr

203 sts revealed elevated liver transaminase and bilirubin levels that were attributed to liver GVHD.

204 dle-aged and elderly adults; instead, direct bilirubin levels were associated with increased risk of

205 sting glucose, triglycerides, uric acid, and bilirubin levels were decreased in the salsalate group c

206 High bilirubin levels were found as a protective factor again

207 Total and indirect bilirubin levels were not significantly associated with

208 ge, total days on oxygen supplement and high bilirubin levels were significant regarding the developm

209 Serum bilirubin levels were significantly decreased by 32% dur

210 ictive value for baseline cholinesterase and bilirubin levels with a highly nonlinear influence for e

211 rogated extravascular hemolysis, normalizing bilirubin levels within 24 hours in most patients and no

212 cantly associated with higher creatinine and bilirubin levels, international normalized ratio, and vi

213 82 newborns showing an increase in newborn's bilirubin levels, the indicator of neonatal jaundice ris

214 th worsening agreement in creatinine at high bilirubin levels.

215 d predisposes the infant to high total serum bilirubin levels.

216 used more elevations in aminotransferase and bilirubin levels.

217 rognostic significance in patients with high bilirubin levels.

218 baseline albumin >/=3.5 g/dL, baseline total bilirubin </=1.2 mg/dL, absence of cirrhosis, and hepati

219 nued to be accurate among individuals with a bilirubin <2.0 mg/dL (C-statistic, 0.90; 95% CI, 0.82-0.

220 LP) > 1.67 x upper limit of normal and total bilirubin <= 2 mg/dL at baseline.

221 re higher albumin (>/=3.5 g/dL), lower total bilirubin (</=1.2 g/dL), absence of cirrhosis, and absen

222 onse range of the sensor (1.0 mM to 0.10 muM bilirubin, measured in a sodium phosphate buffer with pH

223 Newborn screening with direct or conjugated bilirubin measurements detected all known infants with b

224 wo-stage screening with direct or conjugated bilirubin measurements.

225 s syndrome is a common inherited disorder of bilirubin metabolism, characterised by mild, unconjugate

226 ENaC regulation by bile acids and conjugated bilirubin, metabolites that are abundant in the biliary

227 e greater than three times the ULN and total bilirubin more than twice the ULN) after treatment of th

228 blood cell, interleukin-2 receptor, indirect bilirubin, myoglobin, and fibrinogen degradation product

229 he prognosticators of overall survival to be bilirubin, no ascites, tumor size 5 cm or smaller, solit

230 ionic bilirubin ("unbound" bilirubin - i.e., bilirubin not complexed to albumin or other complexing a

231 gamma-glutamyltransferase, without increased bilirubin, occurred in 11 (39%) of 28 patients who recei

232 tal adenocarcinoma (PDAC) and the effects of bilirubin on this index.

233 n of association with either elevated direct bilirubin or GGT; however, PFOA was associated with decr

234 hepatitis flare associated with increase in bilirubin or INR should prompt temporary or permanent ce

235 mic time, peak aspartate transaminase, day 5 bilirubin or international normalized ratio after transp

236 ith omaveloxolone without increases in total bilirubin or other signs of liver injury.

237 rade >/= 3b) after stage 1 (OR = 3.4), serum bilirubin (OR = 4.4), serum creatinine (OR = 5.4), and c

238 rmalities in alanine aminotransferase, total bilirubin, or hemoglobin were observed.

239 quinone glucose dehydrogenase (PQQ-GDH) and bilirubin oxidase (BOD) at anode and cathode, respective

240 Previously we showed that an effective bilirubin oxidase (BOD)-based biocathode using graphene

241 e by the use of high potential cathodes like bilirubin oxidase (BOx) or iron-aminoantipyrine (Fe-AAPy

242 e multi-copper enzyme Myrothecium verrucaria bilirubin oxidase (MvBOD) for direct electron transfer (

243 s mediator, while the cathode catalysts were bilirubin oxidase and [Os(2,2'-bipyridine)2(poly-vinylim

244 ical pre-treatment with a silane derivative, bilirubin oxidase from Myrothecium verrucaria was immobi

245 ehydrogenase from Corynascus thermophiles or bilirubin oxidase from Myrothecium verrucaria, were perf

246 d in biocathode using immobilized laccase or bilirubin oxidase in order to generate sufficient power.

247 notubes, was coupled with an oxygen-reducing bilirubin oxidase on gold nanoparticle dispersed on gold

248 system has a biocathode made from laccase or bilirubin oxidase, and the anode is made from a zinc pla

249 Glucose dehydrogenase-based anode and bilirubin oxidase-based cathode were assembled to a quas

250 nm) and the mono- and trinuclear Cu sites of bilirubin oxidases.

251 Previous studies have suggested that BOXes (bilirubin oxidation end products), originating from rele

252 h catalyzes the degradation of heme into the bilirubin precursor biliverdin, ferrous iron, and CO dur

253 Mrgpra1 or Blvra, the gene that encodes the bilirubin-producing enzyme biliverdin reductase, attenua

254 idic level for the ultimate purpose of total bilirubin quantitation.

255 irubin itself has not been described, and no bilirubin receptor has been identified.

256 al volunteers spiked with varying amounts of bilirubin; results measured using BiliSpec correlated we

257 n at 12 facilities that used universal serum bilirubin screening before (January 1, 2010, through Apr

258 d experimental conditions, the probe detects bilirubin selectively in the presence of other interferi

259 The paper-based potentiometric bilirubin sensor exhibited a response range of 5.0-0.10

260 The components of the potentiometric bilirubin sensor were embedded in a paper-based device t

261 nor after brain death or circulatory death), bilirubin, smoking history, and whether the liver was sp

262 We conclude that bilirubin strongly affects organismal body weight by res

263 d age, preoperative albumin, platelet count, bilirubin, surgery category, emergency indication, fatty

264 n of the construction of the nanoparticulate bilirubin system, primary mechanisms of therapeutic acti

265 Total bilirubin (T-Bil) is an important clinical diagnostic ma

266 Total bilirubin (TB) and serum bile acids (SBA) were highest i

267 ase (ALT), alkaline phosphatase (AST), total bilirubin (TBIL) and direct bilirubin (DBIL) with minima

268 ) was decreased to normal level, while total bilirubin (TBIL) and liver function were significantly i

269 ase [ALT], alkaline phosphatase [ALP], total bilirubin [TBIL], and albumin) at three time points (pre

270 mice; there was no difference in serum total bilirubin (TBili) levels.

271 Recalibration of bilirubin testing instruments.

272 liver inflammation and mean serum levels of bilirubin than mice receiving control antibodies (191 mu

273 the impaired ability of UGT1A1 to eliminate bilirubin that contributes to hyperbilirubinemia-induced

274 fluorescent yellow-pigmented constituents of bilirubin that undergo Z to E isomerization when excited

275 rth that lead to the rapid increase in serum bilirubin, the events that control delayed expression of

276 The probe detects the bilirubin through FRET mechanism.

277 ilation, doubling in creatinine, doubling in bilirubin to >= 2.0 mg/dL, decrease in platelets to < 10

278 mmol/L, doubling in creatinine, doubling in bilirubin to greater than or equal to 2.0 mg/dL, or grea

279 e albumin and platelet count, as well as the bilirubin, transaminases, and alkaline phosphatase, afte

280 ignificant reduction of serum transaminases, bilirubin, triphosphate nick-end labeling staining, casp

281 , which exhibit severe levels of total serum bilirubin (TSB) because of a developmental delay in expr

282 n exposed to excessive levels of total serum bilirubin (TSB) during the neonatal period.

283 undice are based on age-specific total serum bilirubin (TSB) levels.

284 risk from baseline values of cholinesterase, bilirubin, type of primary tumor, age at radioembolizati

285 directly reflecting in elevated unconjugated bilirubin (UCB; main phenotypic feature of GS) and iron,

286 ade of 3 or more based on clinical symptoms, bilirubin, ulcer, pancreatitis, ascites, or radioemboliz

287 embrane, and selectively measures free ionic bilirubin ("unbound" bilirubin - i.e., bilirubin not com

288 nce, it was applied for the determination of bilirubin using both colorimetric and fluorimetric techn

289 97 (R(2) = 0.960) when compared to the total bilirubin values determined in the clinical laboratory.

290 Baseline median serum ALP and bilirubin were 348 U/L (interquartile range 288-439) and

291 line phosphatase (ALP), and total and direct bilirubin were evaluated, and safety was assessed for up

292 ange) for international normalized ratio and bilirubin were highest in group A (3.0 [2.1-3.9] and 16.

293 Center and bilirubin were independently associated with creatinine

294 Center and bilirubin were independently associated with creatinine

295 , glycerophosphoserine, lactosylceramide and bilirubin were lower in the confirmed virus infected gro

296 However, changes in total and direct bilirubin were not significant at other time points.

297 n levels of prothrombin time, INR, and total bilirubin were, respectively, 33% (Q1-Q3, 21-41), 2.74 (

298 ith significant exacerbation of unconjugated bilirubin which persisted through pregnancy.

299 o a Low Molecular Weight (LMW) ACE effector, bilirubin, which act in concert to regulate ACE conforma

300 Stabilisation was also noted for direct bilirubin, with a significant change from baseline at 12